19 November 2026 | Thursday | News
Image Source: Public Domain
Zealand Pharma A/S (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology company transforming metabolic health so millions can live without limits, announces initiation of ZYNERGY, a Phase 2 dose-finding trial in participants with obesity or overweight with at least one weight-related comorbidity. The trial compares once-weekly co-administration of petrelintide (an investigational human amylin analog), and enicepatide (an investigational GLP-1/GIP receptor agonist), versus placebo, petrelintide monotherapy, and enicepatide monotherapy with regards to effect on body weight, safety, and tolerability1.
“The initiation of the Phase 2 trial with petrelintide co-administered with enicepatide marks an important milestone in our ambition to build a leading amylin-based franchise for chronic weight management," said David Kendall, MD, Chief Medical Officer at Zealand Pharma. "As demonstrated in separate Phase 2 trials, petrelintide’s tolerability profile, which is largely comparable to placebo, paired with the promising efficacy of enicepatide, makes this combination study a compelling and natural next step. This study is designed to explore the effect of two complementary mechanisms, aiming to deliver both substantial weight loss and an improvement in cardiometabolic risk markers while maintaining a competitive tolerability profile."
© 2026 Biopharma Boardroom. All Rights Reserved.